Trial reportCell host & microbe2017
Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis.
Open access · bronzeAbstract readClinical Trial
In one paragraph
Trial report in Cell host & microbe, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers.
0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
131 citing papers in PubMed, 181 citations in OpenAlex.
- BCG revaccination boosts adaptive polyfunctional Th1/Th17 and innate effectors in IGRA+ and IGRA- Indian adults.JCI insight · 2019Trial
- Functional, Antigen-Specific Stem Cell Memory (TFrontiers in immunology · 2018Trial
- ESAT-6-derived lipopeptide-based mucosal vaccine elicits distinct humoral immune responses concomitant with a reduction inEmerging microbes & infections · 2026Article
- Antigen-experienced airway CD8Science advances · 2026Article
- Monocytic niches escape T cell surveillance and promote Mycobacterium tuberculosis persistence in lymph nodes.Immunity · 2026Article
- Tuberculosis treatment and cytotoxic immune signatures: a longitudinal study.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- Enhancement of a STING Agonist Vaccine for Tuberculosis Using Locally Supercharged MS2 Viral Capsids.bioRxiv : the preprint server for biology · 2026Article
- mRNA vaccine development for tuberculosis: antigen design, immune mechanisms, and translational challenges.Archives of microbiology · 2026Review
- HowVaccines · 2026Review
- An ESAT-6-convergent prime-boost vaccination combining recombinant BCG expressing Mycobacterium marinum ESX-1 and ESAT-6/GLA-SE improves TB protection.NPJ vaccines · 2026Article
- Optimisation and application of a T-cell antigen-specific activation assay as diagnostic and treatment-monitoring tool for tuberculosis.ERJ open research · 2026Article
- T cell-macrophage interactions in tuberculosis: What we've got here is failure to communicate.Journal of internal medicine · 2026Review
- Enhancing tuberculosis vaccine efficacy with a heterologous mRNA-ChAdOx1 prime-pull strategy targeting lung-resident memory T cells.Frontiers in immunology · 2026Article
- Prophylactic and post-exposure efficacy of a Pichinde virus vector-based tuberculosis vaccine.Frontiers in immunology · 2026Article
- A multiplex Mtb-specific FluoroSpot assay measuring IFNγ, IL-2, and TNF-secreting cells can improve accuracy and differentiation across the tuberculosis spectrum.Journal of clinical microbiology · 2025Article
- Cytotoxic granules and effector molecules from immune cells in tuberculosis: Mechanisms of host defense and therapeutic potential.Virulence · 2025Review
- Human CD4+ T cells recognize Mycobacterium tuberculosis-infected macrophages amid broader responses.The Journal of experimental medicine · 2025Article
- Article
- Finding and filling the knowledge gaps in mechanisms of T cell-mediated TB immunity to inform vaccine design.Nature reviews. Immunology · 2025Review
- Target trial emulation of DPP-4 Inhibitors in patients with T2DM for pulmonary tuberculosis: a nationwide observational data.BMC medicine · 2025Observational
71 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 7 institutions in 3 countries.
Albanus O MogucheCenter for Infectious Disease Research (CIDR), Seattle, WA 98109, USA; Department of Immunology, University of Washington School of Medicine, Seattle, WA 98195, USA.
Munyaradzi MusvosviSouth African Tuberculosis Vaccine Initiative (SATVI), University of Cape Town, Cape Town 7925, South Africa; Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town 7925, South Africa; Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.
Adam Penn-NicholsonSouth African Tuberculosis Vaccine Initiative (SATVI), University of Cape Town, Cape Town 7925, South Africa; Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town 7925, South Africa; Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.
Courtney R PlumleeCenter for Infectious Disease Research (CIDR), Seattle, WA 98109, USA.
Helen MearnsSouth African Tuberculosis Vaccine Initiative (SATVI), University of Cape Town, Cape Town 7925, South Africa; Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town 7925, South Africa; Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.
Hennie GeldenhuysSouth African Tuberculosis Vaccine Initiative (SATVI), University of Cape Town, Cape Town 7925, South Africa; Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town 7925, South Africa; Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.
Erica SmitSouth African Tuberculosis Vaccine Initiative (SATVI), University of Cape Town, Cape Town 7925, South Africa; Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town 7925, South Africa; Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.
Deborah AbrahamsSouth African Tuberculosis Vaccine Initiative (SATVI), University of Cape Town, Cape Town 7925, South Africa; Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town 7925, South Africa; Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.
Virginie RozotSouth African Tuberculosis Vaccine Initiative (SATVI), University of Cape Town, Cape Town 7925, South Africa; Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town 7925, South Africa; Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.
One DintweSouth African Tuberculosis Vaccine Initiative (SATVI), University of Cape Town, Cape Town 7925, South Africa; Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town 7925, South Africa; Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.
Søren T HoffStatens Serum Institut (SSI), 2300 Copenhagen, Denmark.
Ingrid KromannStatens Serum Institut (SSI), 2300 Copenhagen, Denmark.
Morten RuhwaldStatens Serum Institut (SSI), 2300 Copenhagen, Denmark.
Peter BangStatens Serum Institut (SSI), 2300 Copenhagen, Denmark.
Ryan P LarsonCenter for Infectious Disease Research (CIDR), Seattle, WA 98109, USA.
Shahin ShafianiCenter for Infectious Disease Research (CIDR), Seattle, WA 98109, USA.
Shuyi MaCenter for Infectious Disease Research (CIDR), Seattle, WA 98109, USA.
David R ShermanCenter for Infectious Disease Research (CIDR), Seattle, WA 98109, USA.
Alessandro SetteDepartment of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla 92037, USA.
Cecilia S Lindestam ArlehamnDepartment of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla 92037, USA.
Denise M McKinneyDepartment of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla 92037, USA.
Holden MaeckerInstitute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, CA 94305, USA.
Willem A HanekomSouth African Tuberculosis Vaccine Initiative (SATVI), University of Cape Town, Cape Town 7925, South Africa; Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town 7925, South Africa; Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.
Mark HatherillSouth African Tuberculosis Vaccine Initiative (SATVI), University of Cape Town, Cape Town 7925, South Africa; Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town 7925, South Africa; Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.
Peter AndersenStatens Serum Institut (SSI), 2300 Copenhagen, Denmark.
Thomas J ScribaSouth African Tuberculosis Vaccine Initiative (SATVI), University of Cape Town, Cape Town 7925, South Africa; Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town 7925, South Africa; Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa. Electronic address: thomas.scriba@uct.ac.za.
Kevin B UrdahlCenter for Infectious Disease Research (CIDR), Seattle, WA 98109, USA; Department of Immunology, University of Washington School of Medicine, Seattle, WA 98195, USA. Electronic address: kevin.urdahl@cidresearch.org.
South African Tuberculosis Vaccine Initiative · ZACenter for Infectious Disease Research · USStatens Serum Institut · DKUniversity of Cape Town · ZALa Jolla Institute for Immunology · USInfectious Disease Research Institute · USStanford University · US
Funding
Technology CoreU19AI106761 · NIAID · SEATTLE BIOMEDICAL RESEARCH INSTITUTE · PI SHERMAN, DAVID R, ZAK, DANIEL E · 2013 to 2017
$18.9MDiseases of Public Health Importance Training GrantT32AI007509 · NIAID · UNIVERSITY OF WASHINGTON · PI LUND, JENNIFER M · 1997 to 2024
$6.3MT regulatory cells and immunity in tuberculosisR01AI076327 · NIAID · UNIVERSITY OF WASHINGTON · PI URDAHL, KEVIN B · 2009 to 2018
$4.5MHost determinants of protection against tuberculosis in adolescentsR01AI087915 · NIAID · UNIVERSITY OF CAPE TOWN · PI SCRIBA, THOMAS JENS · 2011 to 2015
$3.3MBASIC IMMUNOLOGYT32CA009537 · NCI · UNIVERSITY OF WASHINGTON · PI GOVERMAN, JOAN M · 1986 to 2012
$3.1MFACSAria II Cell SorterS10RR027366 · NCRR · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROFT, MICHAEL · 2011 to 2011
$514kNCI NIH HHS T32 CA009537NIAID NIH HHS HHSN272201300006CNIAID NIH HHS R01 AI076327NIAID NIH HHS R01 AI087915NIAID NIH HHS T32 AI007509NIAID NIH HHS U19 AI106761
Abstract
CD4 T cells are critical for protective immunity against Mycobacterium tuberculosis (Mtb), the cause of tuberculosis (TB). Yet to date, TB vaccine candidates that boost antigen-specific CD4 T cells have conferred little or no protection. Here we examined CD4 T cell responses to two leading TB vaccine antigens, ESAT-6 and Ag85B, in Mtb-infected mice and in vaccinated humans with and without underlying Mtb infection. In both species, Mtb infection drove ESAT-6-specific T cells to be more differentiated than Ag85B-specific T cells. The ability of each T cell population to control Mtb in the lungs of mice was restricted for opposite reasons: Ag85B-specific T cells were limited by reduced antigen expression during persistent infection, whereas ESAT-6-specific T cells became functionally exhausted due to chronic antigenic stimulation. Our findings suggest that different vaccination strategies will be required to optimize protection mediated by T cells recognizing antigens expressed at distinct stages of Mtb infection.
Indexed as
AcyltransferasesAdolescentAnimalsAntigens, BacterialAntigens, Differentiation, T-LymphocyteBacterial ProteinsCD4-Positive T-LymphocytesCell DifferentiationCytokinesFemaleHumansInterferon-gammaLungLymphocyte ActivationMaleMiceAcyltransferasesantigen 85B, Mycobacterium tuberculosisAntigens, BacterialAntigens, Differentiation, T-LymphocyteBacterial ProteinsCytokinesESAT-6 protein, Mycobacterium tuberculosisIFNG protein, mouseInterferon-gammaRNA, MessengerTuberculosis VaccinesAg85BantigensCD4 T celleffector T cellESAT-6memory T cellMycobacterium tuberculosisT cell differentiationvaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.